Verseon presents further trial data on the low bleeding risk of its family of preclinical anti-coagulant drugs

摘要

Fremont, California - Further evidence on the low bleeding profile of Verseon's novel family of anti-coagulants was presented at the BioEurope conference in Stockholm, Sweden recently. The new data reinforces the promise of Verseon's novel, highly selective direct thrombin inhibitors (DTIs) as a potential treatment for venous thrombotic disorders while maintaining a lower bleeding risk than current drugs.